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Abstract
Early diagnosis and intervention are some of the longstanding challenges associated 
with ovarian cancer, which is the leading cause of gynecologic cancer mortality. While 
the majority of patients who present with advanced stage disease at time of diagnosis 
will initially respond to traditional combination platinum and taxane-based chemo-
therapy in conjunction with cytoreductive surgery, approximately 70% will ultimately 
recur due to chemoresistance within the first two years. Intratumor heterogeneity is 
proposed to be a leading factor in the development of chemoresistance and resultant 
poorer outcomes for those with recurrent or advanced stage disease. Both inherent and 
acquired mechanisms of chemoresistance are postulated to be a result of alterations 
in gene expression, also known as epigenetic modifications. Therefore, epigenetic ther-
apy is a pivotal avenue which allows for reversal of chemoresistance in cancer through 
the targeting of aberrant mutations. In this chapter, we discuss how these epigenetic 
modifications prove to be promising targets in cancer therapy leading to heightened 
drug sensitivity and improved patient survival outcomes.
Keywords: cancer therapy, epigenetics, histone deacetylase inhibitors (HDACis), 
DNA methyltransferase inhibitors (DNMTis), tumor microenvironment
1. Introduction
1.1 Chemoresistance causes failure of classic ovarian cancer treatment
Ovarian cancer, similar to other malignancies, is characterized by molecular 
changes in cells which result in unregulated proliferation and spread to other organs 
[1]. Normal regulatory processes are disrupted and therefore aberrant cells are able 
to bypass checkpoints and lead to widespread metastatic potential [2]. Malignant 
ovarian neoplasms contribute to the highest mortality rates among women with 
gynecologic cancers [3]. Among them, high grade serous histologic subtypes are the 
most aggressive with an estimated 21,410 new cases and 13,770 ovarian cancer deaths 
in the United States in 2021 according to the American Cancer Society [4]. Due to 
limited feasibility of screening modalities in low risk patients and vague generalized 
symptoms, many patients are diagnosed at advanced stages contributing to a higher 
rate of treatment failures and poorer prognosis [5]. Traditional initial therapy consists 
of a combination of cytoreductive surgical management and platinum/taxane based 
chemotherapy [6]. The recommended surgical procedure includes a total hysterec-
tomy with removal of bilateral fallopian tubes and ovaries, lymph node evaluation 
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as well as evaluation and removal of all visible disease along the omentum and any 
peritoneal surfaces with full exploration of the abdomen and pelvis [7]. Despite the 
frequent initial success with the aforementioned approach, approximately 70% of 
patients develop recurrent disease either secondary to intrinsic or extrinsic causes of 
chemoresistance [8, 9]. Once the tumor is able to evade standard therapy, treatment 
options then become limited and the disease process is incurable [10]. As a result, 
chemoresistance is one of the leading causes of mortality among advanced stage and 
recurrent ovarian cancer patients. Multiple mechanisms are responsible for inducing 
chemoresistance, and a better understanding of these processes may lead to better 
treatment outcomes for patients with progressive disease [11].
1.2 Histologic subtypes and tumorigenesis
Ovarian cancer can arise from several different cell types including epithelial, 
germ cell and mesenchymal (stromal) origins. These histological classifications 
vary widely with regard to treatment options and prognosis likely secondary to 
unique molecular and biologic features among each subtype [12, 13]. Epithelial 
ovarian cancer (EOC) accounts for 90% of ovarian cancer and can be subdivided 
into high grade serous, low grade serous, endometrioid, clear cell, mucinous, tran-
sitional cell, among several other subtypes with over two-thirds comprising high 
grade serous histology [14, 15]. Among high grade serous lesions, p53 mutations are 
typically omnipresent as well as other important germline and somatic mutations 
(BRCA 1, BRCA 2, and additional homologous recombinant genes), and tend to 
lead to more favorable treatment outcomes [16]. Although these gene mutations 
may induce chemoresistant disease, it is predominantly epimutations and their 
associated changes in gene expression which are thought to drive tumorigenesis. As 
chemoresistance may be innate or acquired even after an initial positive response to 
platinum therapy, it is plausible that genes involved in epigenetic reprogramming 
are controlled by specific transcription factors, and therefore may serve as a poten-
tial target for treatment [17, 18].
As with most malignancies, the staging of ovarian cancer and concurrent 
optimal cytoreduction plays a pertinent role in determining prognosis [19]. Ovarian 
neoplasms are staged surgically and according to the International Federation of 
Gynecology and Obstetrics (FIGO) classification. The 5-year overall survival rate 
differs significantly between early and advanced stage disease at 90% for Stage I 
disease and approximately 15–40% for Stage III/IV disease [20]. As most ovarian 
cancers are diagnosed in advanced stages, an individual’s response to standard 
platinum chemotherapeutic agents becomes a major prognosticator in determining 
outcomes [21, 22].
1.3 Can epigenetic therapy overcome ovarian cancer chemoresistance?
The mainstay approach to treatment of high grade serous carcinomas is with a 
platinum based chemotherapeutic agent whereas other histologic subtypes prove 
to be more chemoresistant [23]. As primary treatments involve a platinum and 
taxane chemotherapeutic agent, an important predictor of progression free and 
overall survival is the platinum-free interval [24]. Patients are classified as platinum 
sensitive should disease recurrence occur greater than 6 months from completion 
of therapy, platinum resistant if less than 6 months and refractory if progression 
occurs through therapy [25]. This subclassification is imperative to predicting which 
patients will likely recur after initial therapy and will require molecular analyses in 
order to determine a more targeted treatment approach. Unfortunately, only 15% of 
patients who develop chemoresistance respond to subsequent therapies and many 
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ultimately will succumb to their disease within one year [26]. Multiple mechanisms 
have been suggested for acquired chemoresistance such as mutations in the cancer 
cells themselves, DNA repair failures as well as epigenetic changes [27–29].
For example, cancer stem cells (CSCs) which are capable of self-renewal,  
differentiation and tumorigenicity have been indicated in the development of 
platinum resistance disease [30, 31]. One particular study demonstrated upregu-
lated expression of stem cell markers CD44, CD133, and ALDH1A1 in recurrent 
ovarian cancer in comparison to primary tumors [32]. DNA repair failures may 
also occur in nucleotide excision, recombination, and mismatch repair pathways 
enabling cancer cells to exploit repair mechanisms and therefore induce an acquired 
chemoresistance [33]. Point of nonsense mutations in oncogenes such as Ras or 
ERK signaling and/or DNA repair genes such as p53, PARP, BRCA 1 and 2 have been 
evidenced to cause chemoresistance and subsequent failure in standard oncologic 
treatments [34]. All in all, cancer renewal and heterogeneity are the main reasons 
for the development of chemoresistance and subsequent failure in standard onco-
logic treatments [35].
Another important component includes epigenetic modifications which result in 
silencing as well as activation of gene expression without DNA sequence alteration 
[36]. The majority of cancers, including ovarian cancer, have aberrant epigenetic 
modifications which result in the promotion of cancer growth, metastasis and 
chemoresistance [37].
1.4 Epigenetics
The field of epigenetics has gained heightened interest in the field of oncol-
ogy over the years. This new concept of study was first described by Conrad 
Waddington in 1942 where he demonstrated the inheritance of an acquired char-
acteristic in a particular population [38]. Although the definition has evolved over 
the years, the overall essence of epigenetics involves the alterations in gene expres-
sion without modification of the DNA sequence itself [39]. In other words, these 
aberrant changes are maintained through cell division without producing a change 
in the overall genetic information [40]. As stated previously, epigenetic alterations 
affect chromatin structure through a variety of mechanisms, altering patterns 
of gene expression. Disruptions in these epigenetic processes can in turn lead to 
altered gene function and further, malignant transformation through oncogene 
activation or tumor suppressor gene silencing [41]. As human cancer cells harbor 
aberrant epigenetic abnormalities, cancer progression is then enabled and mecha-
nisms of resistance develop, which creates an opportunity for targeted therapy 
using epigenetic inhibitors.
Promoter hypermethylation silences crucial genes including but not limited 
to p16, SPARC, CTGF, CDH1 and ICAM-1. Other genes involved in methylation 
dysregulation include PTEN (seen in type 1 ovarian cancers), and those involved 
with suppression of metastasis [42]. Several studies have utilized DNA methyla-
tion assays in order to identify potential epigenetic biomarkers in cell free DNA 
for ovarian cancer in order to improve on early screening challenges [43–45]. This 
method of identification and targeting of differentially methylated regions (DMRs) 
has the potential to identify populations of at-risk patients for the development of 
epithelial ovarian cancers.
Moreover, epigenetic agents have already proved effective in acting as chemother-
apy sensitizers by essentially improving or re-establishing tumor sensitivity as well 
as reversing resistant disease in a multitude of studies [46–48]. Where patients may 
ultimately be classified as platinum resistant, the use of epigenetic agents have the 
potential to reinvoke a response to platinum agents with one study demonstrating 
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a 35% objective response rate after administration of decitabine followed by carbo-
platin among platinum resistant ovarian cancer patients [48]. Therefore, current 
research is concentrated on the development of treatment methodologies involving 
the use of classic chemotherapy in combination or sequentially with epigenetic 
regimens in order to overcome chemoresistance and improve outcomes.
2. Epigenetic aberrations in ovarian cancer
2.1 DNA methylation
One of the most common methods of epigenetic modulation is through DNA 
methylation. Modification of cytosine residues in CpG dinucleotides or CpG islands 
by methylation leads to transcriptional silencing in vertebrates, however, non-CpG 
methylation has also been identified in stem cells [49]. Typically, small amounts of 
CpG island promoters are methylated in normal cells, however, in the presence of 
hypermethylation, tumorigenesis is often incited [50]. The particular enzymes that 
are responsible for DNA methylation are DNA methyltransferases (DNMTs) which 
include DNMT1, DNMT3A, DNMT3A, DNMT3B, and DNMT3C. These enzymes 
are classified as either de novo or maintenance groups, of which de novo are more 
specific to stem cell expression (DNMT3s) whereas DNTM1 is involved in mainte-
nance of DNA methylation during cell division [51].
Both DNA hypomethylation and gene promoter DNA hypermethylation are 
major oncogenic driving factors. Specifically, hypermethylation of promoters on 
tumor suppressor genes BRCA 1 and BRCA 2 lead to their silencing and subsequent 
inactivation of DNA repair driving the development of malignancies such as breast 
and ovarian cancers [51, 52]. However, the earliest methylation errors were of 
reduced activity resulting in increased mutation rates. Notably, transcription of 
repeats, transposable elements (TEs) and oncogenes occurred secondary to changes 
from hypomethylation through the loss of DNMT1 function [41, 53].
2.2 Histone acetylation
DNA is packaged as chromatin which is composed of nucleosomes. In turn, 
the nucleosome is comprised of histone proteins (H3, H4, H2A, H2B) which can 
similarly undergo many modifications and affect DNA transcription, replication 
and repair [54]. A “histone code” exists in order to regulate chromatin structure 
through several different histone modifications, which can lead to either activa-
tion or repression dependent on the residues and type of modification such as 
acetylation, ubiquitylation, sumoylation and phosphorylation [40, 55] (Figure 1). 
Dysregulation of any of these functions can lead to oncogenic activation or even the 
silencing of tumor suppressor genes.
In comparison to DNA methylation, errors in chromatin modification in the 
development of epithelial ovarian cancers is less understood but also pertinent. The 
overexpression of class I histone deacetylases (HDACs) has been identified in sev-
eral cancers, with a prominent association identified in high risk ovarian of serous 
and clear cell subtypes. In addition, an unfavorable prognostic correlation was seen 
in patients with endometrioid histologies [56].
2.3 MicroRNA dysregulation
Along with histone modification and methylation dysregulation, cancer cells are 
prone to errors in microRNA (miRNA) regulation. MiRNAs are small non-coding 
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RNAs of 19–22 nucleotides in length which regulate the expression of certain genes 
either through degradation or inhibition of target mRNA [57]. The expression of 
epigenetic regulators (DNMTs and HDACs) are controlled by these miRNAs in a 
feedback loop of which when dysregulated, can lead to carcinogenic potential [58]. 
Genome analysis reveals condensed areas of miRNAs in cancer-associated genomic 
regions signifying that dysregulation of these particular areas could lead to aberrant 
expression [59]. With regard to epithelial ovarian cancer development, the aberrant 
expression of miRNAs can emulate oncogenic or tumor suppressor activity [60]. 
The overexpression of some types of miRNA as well as decreased activity of others 
were more closely correlated with ovarian cancer cells in comparison to healthy 
ovarian epithelial cells in several studies [61, 62], indicating another potential for 
early diagnostic screening and opportunity for intervention.
3. The clinical application of epigenetic therapies
3.1 DNA methylation inhibitors (DNMTis)
DNA methylation inhibitors (DNMTis) are deoxycytosine analogs. DNMTis 
prevent methyl group transfer by covalently binding to and trapping methyltrans-
ferases [63]. The simplest way to understand the effect of DNMTis is through their 
effect on oncogenes and tumor suppressor genes [64]. BRCA1 and BRCA2 are 
oncogenes that when hypermethylated, can lead to a variety of cancers including 
ovarian cancer [65]. In a similar way, demethylation of tumor suppressor genes 
like p53, MLH1, H1C1, p16, E-cadherin and APC, can also play a role in the genetic 
instability that leads to the development of ovarian cancer, its propagation and 
chemoresistance [64]. Indeed, both demethylation and hypermethylation of the 
genome have been associated with the development of platinum resistance in ovar-
ian cancer [64]. Consequently, DNMTis have been shown in preclinical models to 
restore chemosensitivity and restore normal epigenetics [66].
The most commonly utilized DNA methyltransferase inhibitors are 5-azacti-
dine (AZA) and decitabine (5-aza-2’deoxycytidine) [63]. Both were developed in 
the 1960s for the treatment of hematologic malignancies and are currently FDA 
approved for myelodysplastic syndromes. Both AZA and decitabine have demon-
strated some efficacy in clinical and pre-clinical ovarian cancer studies, however, 
their dose-limiting myelotoxicity limits their practical use. As they can be toxic, 
Figure 1. 
The effect of histone acetylation and deacetylation on DNA transcription.
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other DNMTis are currently under investigation: zebularine, procaine epigallocate-
chin-3-gallate (EGCG) (from green tea extracts), and RG 108 [64].
3.2 Histone deacetylase inhibitors (HDACis)
Histone deacetylase inhibitors (HDACis) act by targeting the zinc ion required 
for the catalytic function of the class I, II and IV HDACs [64]. The class III HDACs 
are not zinc dependent and are not inhibited by any of the current HDACis. HDACis 
are stratified by activity and chemical structure. There are pan-HDAC inhibi-
tors, which affect classes I, II and IV, as well as class-specific inhibitors [67]. The 
chemical structure of HDACis include: hydroxamic acids, cyclic tetrapeptides, 
benzamides, and short-chain aliphatic acids [67]. They act on ovarian cancer in 
the alteration of gene transcription and chromatin remodeling [64]. In doing so, 
HDACis arrest cell growth, promote apoptosis, and inhibit angiogenesis [64].
The largest group of HDACis are the hydroxamic acids: vorinostat (suberanilo-
hydroxamic acid or SAHA), belinostat, and panobinostat, all of which are pan-
HDAC inhibitors FDA approved for hematologic malignancies [64]. Romidepsin, 
a tetrapeptide, has specific activity against Class I HDAC and is currently FDA 
approved for the treatment of cutaneous t-cell lymphoma [64]. Another HDACi in 
this group is etinostat [64]. Valproic acid is a short-chain aliphatic acid and is overall 
a weak HDACi with little clinical utility [64].
Since aberrant DNA methylation and histone acetylation contribute to the pro-
gression, metastasis and chemoresistance of high grade serous ovarian cancer, epigen-
etic drugs are thought to have the capability of reversing these effects (Figure 2).
3.3 Other epigenetic therapies
While DNMTis and HDACis have been more extensively studied, other 
epigenetic therapies are on the horizon. These drugs target methylation and 
Figure 2. 
The Role of DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis) in 
halting tumorigenesis.
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phosphorylation of the cancer genome. Examples are small molecule inhibitors tar-
geting the histone lysine methyltransferases EZH2 and inhibitors of bromodomain 
proteins, BET inhibitors [64]. G9A is one such target. It is a histone methyltransfer-
ase that demethylates H3K9 and is detected in 71.6% of metastatic high grade serous 
cancers [68]. JQ1 is an agent that targets the bromodomain and extraterminal (BET) 
protein BRD4 [68]. In preclinical models, JQ1 has suppressed BRD4 and restored 
cisplatin sensitivity in ovarian cancer [68]. Furthermore, JQ1 has been shown by 
other researchers to synergize with PARP inhibitors in ovarian cancer cells that are 
proficient in homologous recombination [68, 69]. These newer epigenetic therapies 
hold promise, but still need further investigation.
3.4 Efficacy of different inhibitors
It is important to note that in pre-clinical models, epigenetic therapies are more 
active against tumor cells, while normal cells appear to be resistant to their effects. 
[64] Yet, this is a double-edge sword. Because epigenetic regulators have a broad 
impact over the entire genome, there will be great anti-tumor effects, but also 
unintended nonspecific consequences [68]. These nonspecific effects explain the 
toxicities seen in the clinical trials done with epigenetic therapies.
4. Relevant clinical trials using epigenetic therapy in ovarian cancer
4.1 Success and failures
Clinical translation studies with epigenetic therapy have had mixed results, 
but the most success with epigenetic therapy appears to be when it is used in 
combination with other agents and at the lowest effective dose [64]. This was 
discovered with one of the first epigenetic clinical trials in 2008, when the 
Gynecologic Oncology Group learned that as a single agent, SAHA is not very 
effective. They conducted a phase II study of vorinostat (SAHA) in the treatment 
of 27 platinum resistant patients. While 9 of 27 patients had stabilization of their 
disease, only 1 of 27 had a partial response and only 2 patients had a progression 
free survival of greater than 6 months [70]. In 2013, Mendivil and colleagues 
conducted a study where vorinostat was given in combination with paclitaxel 
and carboplatin to 18 patients as upfront therapy. The investigators reported a 
50 percent total response rate, however, the study was closed prematurely due to 
safety concerns. Patients suffered grade 3 and 4 neutropenia. Additionally, three 
bowel perforations effected closure of the study [71]. Matulonis et al. in 2015 
conducted a phase 1 trial of platinum sensitive patients at their first recurrence 
again using vorinostat. In this trial, vorinostat was given with gemcitabine and 
carboplatin. This combination has also demonstrated some efficacy in the recur-
rent setting but had significant hematologic toxicity, namely, thrombocytopenia 
and neutropenia [72].
Fu and colleagues used azacitidine (AZA) to re-sensitize 17 platinum resistant 
patients to carboplatin in a phase Ib-II trial [73]. While the numbers were small, a 
partial response was noted in 70 percent of patients with an overall response rate of 
22 percent [73]. Notably, these investigators gave their patients 5 days of AZA prior 
to carboplatin [73]. As it appears, epigenetic therapies may be most advantageous 
when used to augment classic chemotherapy and even immunotherapy, as opposed 
to being given in isolation or in combination with an existing regimen.
Oza and colleages recently conducted a larger study with 103 patients [74]. It 
randomized patients to guadecitabine and carboplatin versus investigator’s choice 
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(topotecan, pegylated liposomal doxorubicin, paclitaxel or gemcitabine) until 
disease progression or unacceptable toxicity. Cross-over was allowed from the stan-
dard arm to the experimental arm and 27 patients crossed-over. The combination 
of guadecitabine and carboplatin was found to be effective, however the median 
progression free survival of 16 weeks when compared to the 9 weeks in the standard 
treatment arm was not found to be statistically significant [74].
4.2 The administration of epigenetic therapy – better together?
One approach to utilizing epigenetic therapy effectively up front is in alternating 
treatments of classic chemotherapy and epigenetic therapy. This method was found 
to be effective and less toxic in clinical translational studies [73, 74]. Sequential 
administration of classic chemotherapy and epigenetic drugs not only suppresses 
ovarian cancer growth in vitro, but also spares toxicity to normal cells and preserves 
the healing ability of stem cells [75]. Furthermore, chemotherapy and epigenetic 
therapy act synergistically allowing smaller doses of both to be administered. In 
turn, this decreases the toxicity of both chemotherapy and epigenetic therapy [69]. 
This methodology has yet to be broadly adopted in clinical trials involving epigen-
etic therapy.
For recurrent disease, epigenetic therapy may have utility. Epigenetic therapy 
restores platinum sensitivity as both hypermethylation and histone modifica-
tion contribute to chemoresistance, reversing these epigenetic changes, should 
reverse the chemoresistance [64]. This has been borne out in the literature as 
less than 10 percent of platinum resistant patients would be expected to respond 
to platinum again, yet pretreatment with AZA yields a 22 percent response and 
decitabine, a 35 percent response [64]. Taxol resistance has not been as heavily 
explored in the literature as platinum resistance, however, epigenetic therapy, 
may re-sensitize ovarian cancer to paclitaxel as it does cisplatin. In one preclini-
cal study, the HDACi panobinostat was used to re-sensitize ovarian cancer cell 
lines that had become resistant to paclitaxel [76]. These researchers were further 
able to demonstrate that when human ovarian cancer xenografts were implanted 
in a murine model, panobinostat in combination with cisplatin and paclitaxel 
was superior in efficacy to cisplatin-paclitaxel or panobinostat alone [76]. Thus, 
epigenetics may possibly be used upfront to “prime” or increase the efficacy of 
classic chemotherapy. Additionally, they may be sequenced in between classic 
chemotherapy and again when patients recur to re-sensitize them to platinum 
and taxol agents.
5. Future directions in improving patents care outcomes
5.1 Epigenetics and immunotherapy
There is biologic plausibility that epigenetic therapies can prime tumors for a 
better response to immunotherapy and turn “cold” tumors into “hot” ones [68]. For 
example, in one murine model, the combination of decitabine and anti-CTLA-4 sig-
nificantly shrunk tumors and prolonged survival as compared to either agent alone 
[77]. There is additional preclinical data suggesting that AZA can upregulate T-cells 
in murine models [78]. Additionally, two clinical trials are currently underway. The 
results from one study of 75 patients are expected in March 2022 (NCT03206047). 
Its investigators are looking at AZA and atezolizumab with or without the anti-
NY-ESO-1 vaccine (a biologic agent) in women with recurrent platinum resistant 
ovarian cancer. The other study is looking at guadecitabine with pembrolizumab for 
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recurrent ovarian cancer (NCT02901899). Thirty-five patients have been enrolled 
in this latter study and results are expected in March 2022.
5.2 Epigenetics and precision medicine
The heterogeneity of ovarian cancer is such that no two tumors are alike, 
however, tumors expressing similar genetic profiles, have been shown to respond 
to agents targeting their specific genetics. Recent clinical trials indicate that ovarian 
cancer patients with homologous recombination deficiency, for example, respond 
well to PARP inhibition [79, 80]. Newer epigenetic therapies like BET inhibitors, 
have the ability enhance PARP inhibition [69]. Another clinical challenge in ovarian 
cancer is the ARID1A mutation. Ovarian cancers with this mutation are associated 
with late-stage disease at diagnosis and early recurrence [81]. Roughly 50 percent of 
clear cell carcinomas, which are notoriously chemoresistant, harbor this mutation. 
In one murine model, the HDACi vorinostat was found to be highly effective against 
ARID1A mutated ovarian cancer [81]. Thus, epigenetics may help further precision 
medicine and the targeting of actionable mutations.
6. Conclusion
Platinum resistant and recurrent ovarian cancer patients have very little in the 
way of highly effective treatment. Chemotherapy may be effective for a period of 
months or a few years for these patients, but it is rarely if ever curable. Epigenetic 
therapies hold promise, especially in conjunction with other mechanisms, like 
PARP inhibitors and immunotherapy, but the timing, dosing and patient selection 
must be fine-tuned before they can enter the mainstream of treatment for ovar-
ian cancer.
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